---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-020490"
form_type: "8-K"
ticker: "DNA"
cik: "0001830214"
company_name: "Ginkgo Bioworks Holdings, Inc."
filed_at: "2023-05-10T23:59:59+00:00"
generated_at: "2026-06-15T06:59:42.684177+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Ginkgo Bioworks Q1 revenue $81M, down 52% YoY; Cell Engineering rev up 59%

## Summary
- Q1 2023 total revenue $81M (down 52% YoY); Cell Engineering rev $34M (+59% YoY); Biosecurity rev $47M (52% gross margin).
- Operating loss $(216)M (incl. $75M SBC); Adj. EBITDA $(100)M vs $(1)M prior year. Cash ~$1.2B.
- Added 13 new Cell Programs (18% YoY growth); FY2023 outlook: at least 100 new programs, total rev ≥$275M.
- Acquired StrideBio's AAV capsid engineering platform to advance gene therapy capabilities.

## SEC filing metadata
- accession: 0000950170-23-020490
- form_type: 8-K
- ticker: DNA
- cik: 0001830214
- company_name: Ginkgo Bioworks Holdings, Inc.
- filed_at: 2023-05-10T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1830214/000095017023020490/0000950170-23-020490-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1830214/000095017023020490/dna-20230510.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-020490
- JSON: https://secwatch.observer/filing/0000950170-23-020490.json
- Plain text: https://secwatch.observer/filing/0000950170-23-020490.txt

## Key facts
- Earnings Releases
  Ginkgo Bioworks Holdings, Inc. reported first quarter ended March 31, 2023 results: revenue $81 million. Guidance reaffirmed.
  - Period: first quarter ended March 31, 2023
  - Revenue: $81 million
  - Guidance: reaffirmed
  - Result: reported results
  source text: First quarter 2023 Total revenue of $81 million, down from $168 million in the comparable prior year period, a decrease of 52% driven by the expected ramp down of K-12 testing in Ginkgo’s Biosecurity business unit
  evidence_url: https://www.sec.gov/Archives/edgar/data/1830214/000095017023020490/0000950170-23-020490-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.